T1	Participants 112 127	ovarian cancer.
T2	Participants 321 341	ovarian cancer (OC).
T3	Participants 350 378	Patients with stage IC-IV OC
T4	Participants 601 637	Patients with complete response (CR)
T5	Participants 876 885	toxicity.
T6	Participants 886 913	PD or death in 636 patients
T7	Participants 1089 1142	by 820 of 919 patients enrolled; 352 patients with CR
T8	Participants 1177 1208	whereas 155 patients without CR
